|
More insights in clinical trials with inclisiran ORION-2 shows benefit in patients with homozygous familial hypercholesterolaemia with reductions in LDL cholesterol of about 30%. These results provided a basis for the ORION-5 study, a randomised trial in patients with homozygous familial hypercholesterolaemia. |
|
Novel PCSK9 inhibitor LIB003 looks good This phase 2 trial showed reductions in LDL cholesterol of more than 70% with a 4-week dosing schedule; phase 3 development continues. |
